Study Evaluating Inhaled AeroLEF Delivered in 4 Aerosol Delivery Devices in Healthy Volunteers

NCT00794209 | Completed Phase 1

• 1 other identifier: LEF-07
• Study Type: interventional
• Target: 9
• Locations: 0 countries
• Sites: N/A

Brief Summary

This was an open-label, two-phase, crossover, safety, pharmacokinetic (PK), and pharmacodynamic (PD) study in normal, healthy, non-smoking, fasting male and female subjects. The first phase (A. Device Qualification Phase) of the study compared three aerosol devices to a reference device to identify a nebulizer that produced a favourable, clinically relevant, PK and PD profile of AeroLEF. The PK and PD of the test and reference devices were compared to 200 mcg of intravenous fentanyl administered over 1 minute. The second phase (B. Device Characterization Phase) of the study was planned to characterize and compare the safety, PK and PD of the selected aerosol device (identified in the Device Qualification Phase) to 300mcg of intravenous fentanyl administered over 15 minutes if a device was chosen during the Device Qualification Phase. The data from the selected aerosol device would be pooled from subjects in both the Device Qualification and Device Characterization Phases of the study.

Conditions

Healthy

Keywords

AeroLEF, fentanyl, liposome encapsulated, opioid

Outcome Measures

Primary Outcomes (1)

• To identify an aerosol device which maintains the plasma fentanyl concentration above the lower limit of the therapeutic range (> 0.5 ng/mL) for at least 2 hours longer than the AeroEclipse breath-actuated nebulizer

  duration of 2 months

Secondary Outcomes (1)

• To characterize and compare the pharmacokinetic, pharmacodynamic and safety profiles of single inhaled doses of AeroLEF (liposome encapsulated fentanyl, 500 mcg/mL)

  2 months

Study Arms (1)

1

EXPERIMENTAL

Drug: i.v fentanyl, AeroLEF

Interventions

i.v fentanyl, AeroLEF DRUG

* i.v fentanyl * 5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas) * 5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois) * 5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario) * 3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device.

Also known as: fentanyl, AeroLEF

1

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female between 18 and 65 years, inclusive. No history of smoking for greater than or equal to 12 months, and no smoking within the past year by self-report.
• Body weight with a Body Mass Index (BMI) range of 18.5 -- 27.0, with a minimum weight of at least 60 kg.
• Normal findings in the physical examination and vital signs (blood pressure between 100-150/60-90 mmHg, heart rate between 55-99 beats, respiration 12--24/min) and no clinically significant findings in a 12-lead electrocardiogram (ECG).
• Negative urine screen for drugs of abuse.
• Negative tests for smoking tobacco (carbon monoxide (CO) breath test), alcohol (breath test), hepatitis B-surface antigen, hepatitis C antibody, and HIV at screening.
• No clinical laboratory values outside of the laboratory normal reference range, unless the Principal Investigator decided they were not clinically significant.
• Female subjects: (a) if pre-menopausal, and were not pregnant prior to study start and would avoid pregnancy during the study and up until one (1) month after the end of the study by the use of adequate contraceptive precautions (abstinence or the use of two effective methods, e.g. oral contraceptive pill and condom with spermicidal foam), or (c) were surgically sterile for at least 6 months, or (d) post-menopausal for at least 1 year.
• Female subjects of childbearing potential must have negative pregnancy tests at screening (serum test) and prior to dosing at each treatment session (urine test).
• Ability and willingness to communicate well with the investigator and to comply with the requirements of the entire study.
• Willingness to give written informed consent (prior to any study-related procedures being performed) and was able to adhere to the study restrictions, appointments, and examination schedule.

You may not qualify if:

• Known history of hypersensitivity to fentanyl (e.g. Fentanyl citrate, Actiq, Duragesic, Sublimaze®) and/or related opioid analgesic drugs such as: alfentanil HC1 (Rapifen®), amleridine, butorphanol tartrate (Stadol NSA®), codeine (Tylenol® No. 3), hydrocodone (Tussionex®, Hycodan®, Hycomine®), hydromorphone (Dilaudid®), methadone, morphine (MS Contin®), nalbuphine (Nubain®}, oxycodone (Percocet®, Percodan®, oxymorphone (Numorphan®), pentazocine (Talwin®), pethidine, meperidine (Demerol®), propoxyphene (Darvon®, dextropropoxyphene), remifentanil (Ultiva®), or sufentanil.
• History of violent behaviour under the influence of opioids.
• Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, neuromuscular, neurological, hematological, liver or kidney disease, or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
• Known history of chronic bronchitis or other bronchospastic condition.
• Any known nasal cavity abnormality or aversion to this route of drug administration.
• History of glaucoma or any other pupil abnormalities that, in the opinion of the Principal Investigator, would interfere with the ability to perform the pupillometry measurements.
• Any clinically significant illness during the last four (4) weeks prior to entry into this study which, in the opinion of the Principal Investigator, would introduce additional risk for the study subject, or was likely to interfere with the successful collection of the measures required.
• Presence of any significant physical or organ abnormality that, in the opinion of the Principal Investigator, would introduce additional risk for the study subject, or was likely to interfere with the successful collection of the measures required.
• Any subject with a lifetime history of dependency on opiates by DSM-IVr criteria or any other drugs of abuse.
• Any current major is I psychiatric disorder for which the subject was currently receiving treatment or which would make study compliance an issue, or a history of severe neurological disease, such as head injury or recurrent seizures.
• Use of any prescription medication within 30 days preceding entry into this study, including any enzyme-inducing or enzyme-inhibiting drugs (with the exception of oral, depot or injectable contraceptives for women).
• Use of over-the-counter (OTC) medication within 14 days preceding entry into this study (excluding OTC products known to not affect the cytochrome P450 system, and OTC contraceptive products).
• Participation in a clinical trial with an investigational drug within 30 days preceding this study.
• Subjects who received treatment in the Device Qualification Phase of this study was to be excluded from participation in the Device Characterization Phase of this study.
• Blood donation or other blood draws within 45 days prior to enrolment in the study resulting in a total withdrawal of 100 mL or greater.

Sponsors & Collaborators

• YM BioSciences: lead

MeSH Terms

Interventions

Fentanyl

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Edward M Sellers, MD

  Ventana Clinical Research Corporation

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 13, 2008
• First Posted: November 19, 2008
• Study Start: March 1, 2003
• Primary Completion: May 1, 2003
• Study Completion: May 1, 2003
• Last Updated: November 19, 2008

Record last verified: 2008-11